Analysed EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) News Sources
Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight
17-08-2026
yahoo.com
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
13-07-2026
yahoo.com
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
13-07-2026
yahoo.com
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
22-09-2026
yahoo.com
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
25-09-2026
yahoo.com
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
03-10-2026
yahoo.com
What is the current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is $39.06.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is $-0.17.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is -0.4333%.
What is the most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is .
SEC-8K** Filing Available For EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.